Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on developing novel antibody-based therapies for oncology indications. The company completed its business combination with Brookline Capital Acquisition Corp, a blank-check company sponsored by Brookline Capital Markets, in 2021, bringing Apexigen to the public markets through the SPAC route. The December 2021 quarterly filing on Form 10-Q reflects Apexigen's status as a newly public entity operating in the biotechnology and oncology sector, advancing its pipeline of cancer immunotherapy candidates. For comprehensive data on Apexigen, BCAC, and thousands of other SPAC transactions and filings, sign up for full access at SpacDesk.